éå»1ã¶æéã«Supernus Pharmaceuticals Incã«å¯ŸããŠè©äŸ¡ãåºããã¢ããªã¹ã5åã«åºã¥ãããŒã¿ã
仿ãSUPNã¯3ä»¶ã®ãè²·ããã1ä»¶ã®ãäžç«ïŒããŒã«ãïŒãã0ä»¶ã®ã売ããè©äŸ¡ãç²åŸããŸãããçŽè¿1ã¶æã«ãããSUPNã®ã¢ããªã¹ãå¹³åç®æšæ ªäŸ¡ã¯62.600ã§ãã
ã¢ããªã¹ãäºæ³ã«ãããšãFY2026Q2ã«çºè¡šãããEPS -1.005ã«ç¶ããSUPNã®FY2026Q3ã®EPSã¯0.615ã«éããèŠéãã§ããçºè¡šãããå®çžŸå€ãšäºæ³ãæ¯èŒããŠãåçæ§ã®æšç§»ã確èªããŸãããã
åžå Žäºæ³ã¯ USD -1.01 ã§ããããSupernus Pharmaceuticals IncSUPN ã®åååæã®äžæ ªåœããå©ç (EPS) 㯠USD -0.04 ã§ãããæ¬¡ã®ååæã® EPS 㯠USD 0.61 ãšäºæ³ãããŸãã